Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Generics First
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Blog
Commitment to Quality
Press Releases
Events
All Events
Access! 2027
GRx+Biosims 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Generics First
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Blog
Commitment to Quality
Press Releases
Events
All Events
Access! 2027
GRx+Biosims 2027
JOIN
SEARCH
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
June 25, 2024
AAM
Senate Finance Committee Bill Addressing Drug Shortages Would Provide Long Overdue Relief from Penalties Hurting Generic Drug Market
Blog
April 16, 2024
AAM
Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
Blog
February 22, 2024
AAM
Access! 2024 – Charting a Sustainable Path for Generics and Biosimilars
Blog
October 20, 2023
AAM
2023 Report
Blog
October 18, 2023
AAM
GRx+Biosims 2023 Conference Recap
Blog
September 13, 2023
AAM
Member Spotlight: Biocon Biologics
Blog
July 17, 2023
AAM
Pharmacy Benefit Managers Are Blocking Patient Access to Biosimilar Insulin
Blog
June 28, 2023
AAM
U.S. Patients Rely On Generic Medicines But Increases In Drug Shortages Reflect Challenges To Their Long-Term Sustainability
Blog
May 12, 2023
AAM
Associate Members Spotlight: Antheia
Blog
May 10, 2023
AAM
Shamekka Shares Why We Should Never Take Moms #4GRxANTED
Blog
February 24, 2023
AAM
A Look Back at Access! 2023
Blog
February 9, 2023
AAM
The Quickest Route to U.S. Essential Medicines Production: Existing and Idle Production Sites
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2027
GRx+Biosims 2027
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Generics First
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Blog
Commitment to Quality
Press Releases
Events
All Events
Access! 2027
GRx+Biosims 2027
JOIN
SEARCH